Oramed reports Q3 EPS (18c), consensus (25c)

Reports Q3 revenue $682K, consensus $690K. "We are pleased to share our quarterly report for Q3. We had a strong quarter filled with important milestones, including positive Phase 2 NASH data and initial positive results from our Phase 1 oral Covid-19 vaccine trial. Over the next few months, we look forward to sharing multiple milestones, most notably topline data from our first Phase 3 oral insulin trial expected in January," said CEO Nadav Kidron. "Oramed remains in a strong financial position with approximately $160M in cash and investments as of September 30, 2022, allowing us to continue advancing all aspects of our pipeline and giving us sufficient runway to complete our pivotal oral insulin (ORMD-0801) Phase 3 trials and advance us towards potential FDA approval."